drugset
drugset / Trial / NCT07115485

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07115485 ↗

Phase 2 Recruiting 60 enrolled Shanghai Henlius Biotech
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Timeline

Start
2025-09-15
Primary completion
2027-08-30
Completion
2028-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HLX43 Other / unclassified 2 mg/kg Intravenous
Subject HLX43 Other / unclassified 2.5 mg/kg Intravenous
Subject HLX43 Other / unclassified 3 mg/kg Intravenous

Indications

gastroesophageal adenocarcinoma